CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon

Publication | Open Access

DOI Full Paper Access

Citations

References

2014

Year

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, M. R. Mahoney, Bert H. O’Neil, Jawaid Shaw, Blasé N. Polite, Howard S. Höchster, J. Atkins,

Annals of Oncology

Calgb/swog 80405Kras Wild-typeGastrointestinal OncologyMedicinePhase Iii TrialColorectal CancerPathologyCancer TreatmentOncologyRadiation OncologyMolecular Oncology